Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BTG appoints non-exec director

This article was originally published in Scrip

Executive Summary

BTG, a specialist healthcare company developing and commercializing products targeting critical care, cancer and other disorders, has named Susan Foden a non-executive director of its board – effective 1 March 2015. Dr Foden is currently chair of BerGenBio and Cizzle Biotech, holds non-executive roles with Vectura Group, Evgen and Source Bioscience and is an advisory board member for CD3 (a joint initiative between Leuven University and the European Investment Fund).  Previously Dr Foden has held the positions of investor director with the venture capital firm Merlin Biosciences, CEO of the technology transfer company Cancer Research Campaign Technology, and head of academic liaison at Celltech.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts